A detailed history of First Capital Advisors Group, Llc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, First Capital Advisors Group, Llc. holds 6,947 shares of GILD stock, worth $652,670. This represents 0.29% of its overall portfolio holdings.

Number of Shares
6,947
Previous 7,067 1.7%
Holding current value
$652,670
Previous $586,000 8.7%
% of portfolio
0.29%
Previous 0.38%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 15, 2023

SELL
$76.01 - $86.7 $9,121 - $10,404
-120 Reduced 1.7%
6,947 $535,000
Q1 2023

May 15, 2023

BUY
$77.31 - $88.08 $1,700 - $1,937
22 Added 0.31%
7,067 $586,000
Q4 2022

Feb 14, 2023

SELL
$62.32 - $89.47 $67,679 - $97,164
-1,086 Reduced 13.36%
7,045 $604,000
Q3 2022

Nov 14, 2022

BUY
$59.54 - $68.01 $70,554 - $80,591
1,185 Added 17.06%
8,131 $502,000
Q2 2022

Aug 15, 2022

BUY
$57.72 - $65.01 $400,923 - $451,559
6,946 New
6,946 $429,000
Q4 2021

Mar 02, 2022

SELL
$64.88 - $73.64 $515,471 - $585,069
-7,945 Closed
0 $0
Q4 2018

Feb 07, 2019

SELL
$60.54 - $79.0 $80,094 - $104,517
-1,323 Reduced 14.27%
7,945 $497,000
Q3 2018

Oct 24, 2018

BUY
$71.28 - $78.92 $28,369 - $31,410
398 Added 4.49%
9,268 $716,000
Q2 2018

Jul 30, 2018

BUY
$64.88 - $75.68 $74,612 - $87,032
1,150 Added 14.9%
8,870 $628,000
Q1 2018

Apr 11, 2018

SELL
$72.84 - $88.8 $9,979 - $12,165
-137 Reduced 1.74%
7,720 $582,000
Q4 2017

Jan 25, 2018

BUY
$71.15 - $83.52 $46,460 - $54,538
653 Added 9.06%
7,857 $0
Q3 2017

Oct 31, 2017

BUY
$72.11 - $85.47 $519,480 - $615,725
7,204
7,204 $584,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track First Capital Advisors Group, Llc. Portfolio

Follow First Capital Advisors Group, Llc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Capital Advisors Group, Llc., based on Form 13F filings with the SEC.

News

Stay updated on First Capital Advisors Group, Llc. with notifications on news.